SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 73 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 0.59 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $867,000 | +182.4% | 79,000 | +125.7% | 0.02% | +400.0% |
| Q4 2019 | $307,000 | +17.6% | 35,000 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $261,000 | -19.9% | 35,000 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $326,000 | -60.4% | 35,000 | -65.6% | 0.00% | -50.0% |
| Q3 2018 | $823,000 | +131.8% | 101,800 | +101.6% | 0.01% | +100.0% |
| Q2 2018 | $355,000 | -50.6% | 50,500 | 0.0% | 0.00% | -50.0% |
| Q1 2018 | $719,000 | +62.7% | 50,500 | 0.0% | 0.01% | +60.0% |
| Q4 2017 | $442,000 | -25.2% | 50,500 | 0.0% | 0.01% | -28.6% |
| Q3 2017 | $591,000 | -16.2% | 50,500 | 0.0% | 0.01% | -12.5% |
| Q2 2017 | $705,000 | +1.7% | 50,500 | 0.0% | 0.01% | 0.0% |
| Q1 2017 | $693,000 | – | 50,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |